HIV Drugs Market Report 2026

The hiv drugs market size has grown steadily in recent years. It will grow from $36.55 billion in 2025 to $37.69 billion in 2026 at a compound annual growth rate (CAGR) of 3.1%. The growth in the historic period can be attributed to approval of first antiretroviral drugs, widespread awareness campaigns, expansion of hiv testing programs, growth of global healthcare infrastructure, initial government funding for hiv research.

The hiv drugs market size is expected to see steady growth in the next few years. It will grow to $43.08 billion in 2030 at a compound annual growth rate (CAGR) of 3.4%. The growth in the forecast period can be attributed to emergence of long-acting therapies, advancement in precision medicine, integration of ai in drug discovery, expansion of healthcare access in emerging markets, development of combination antiretroviral therapies. Major trends in the forecast period include personalized antiretroviral therapy, long-acting injectable hiv drugs, hiv drug resistance monitoring, combination therapy development, access programs in emerging markets.

Growing awareness about the diagnosis and treatment of HIV is a significant driver of the HIV drug market. Awareness of HIV refers to people’s knowledge of its diagnosis, treatment, and prevention, enabling timely detection and management. Increased awareness encourages early testing and treatment, which improves health outcomes and reduces transmission. HIV drugs also help reinforce public understanding by emphasizing the importance of treatment and prompting individuals to get tested and seek care. For example, in July 2024, according to the United Nations International Children's Emergency Fund (UNICEF), a US-based humanitarian organization, an estimated 40 million people were living with HIV worldwide in 2023. Therefore, rising awareness regarding HIV diagnosis and treatment is fueling the growth of the HIV drug market.

Increased government spending is expected to boost the growth of the HIV drug market in the coming years. Government spending, also referred to as public expenditure, is the allocation of funds to support various programs and services. Enhanced government funding supports research and development, improves access to treatments, raises awareness, and reduces the societal and economic burden of HIV. These investments positively impact market growth and the effectiveness of HIV management efforts. For example, in March 2023, according to the U.S. Government Budget report, President Joe Biden's Fiscal Year (FY) 2024 budget proposed around $850 million for the CDC, HRSA, IHS, and NIH to sustain and expand the Ending the HIV Epidemic initiative in the U.S. - a 48% increase of $277 million compared to FY23 funding. Consequently, increased government spending is driving the expansion of the HIV drug market.

Key companies in the HIV drugs market are establishing strategic partnerships to manufacture Lenacapavir, aiming to accelerate drug development, expand access, and strengthen their global presence. Lenacapavir is a first-in-class HIV-1 capsid inhibitor that works effectively in combination with other antiretrovirals and targets multiple stages of the HIV lifecycle, making it a promising option for patients with limited treatment alternatives. For instance, in August 2023, Dr. Reddy's Laboratories and Hetero, both India-based pharmaceutical companies, partnered with Gilead Sciences Inc., a US-based biopharmaceutical company, to manufacture and distribute Lenacapavir in 120 primarily low- and lower-middle-income countries (LMICs). This initiative is intended to broaden access to this innovative therapy, particularly for heavily treatment-experienced patients with multi-drug-resistant HIV.

Major companies operating in the hiv drugs market are Gilead Sciences Inc., Johnson & Johnson, Merck & Co. Inc., Boehringer Ingelheim International GmbH, Cipla, Aurobindo Pharma, AbbVie, Emcure Pharmaceuticals, Micro Labs Limited, Northeast Pharmaceutical Group Co. Ltd, Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries Ltd, Strides Arcolab Limited, Hetero Labs Limited, Shanghai Desano Bio-pharmaceutical Co., Anhui Biochem Biopharmaceutical Co. Ltd., Shanghai Xinxing Medicine Co. Ltd., China Meheco Xinxing Pharma Co. Ltd., CytoDyn Inc., Janssen Pharmaceutical, Roche Laboratories, Mylan N.V., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Teva Canada, ViiV Healthcare Canada, GSK, Abbott Laboratories, Aspen Pharmacare Limited, Pharmacare Ltd.

North America was the largest region in the HIV drugs market share in 2025. Middle East is expected to be the largest growing region in the global HIV drug market during the forecast period. The regions covered in the hiv drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hiv drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the HIV drugs market by increasing the cost of imported active pharmaceutical ingredients (APIs) and raw materials, leading to higher production expenses. The oral and parenteral segments, particularly in regions like North America, Europe, and Asia-Pacific, are most affected due to reliance on global supply chains. While costs have risen, tariffs have also encouraged some manufacturers to localize production and invest in regional manufacturing capabilities, creating opportunities for cost optimization and supply chain resilience.

The hiv drugs market research report is one of a series of new reports that provides hiv drugs market statistics, including hiv drugs industry global market size, regional shares, competitors with a hiv drugs market share, detailed hiv drugs market segments, market trends and opportunities, and any further data you may need to thrive in the hiv drugs industry. This hiv drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

HIV drugs are antiretroviral medications commonly used to treat HIV. These drugs prevent the human immunodeficiency virus (HIV) or other retroviruses from spreading within the body. If left untreated, HIV can lead to AIDS (acquired immunodeficiency syndrome). Currently, there is no fully effective cure.

The main types of HIV drugs include nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors, integrase inhibitors, fusion inhibitors, chemokine receptor inhibitors, and others. NRTIs are structural nucleoside analogs of DNA nucleotides that block HIV-1 reverse transcriptase and viral replication by preventing reverse transcription of the HIV genome. These drugs are administered orally or parenterally and are available through hospital pharmacies, retail pharmacies, online pharmacies, and other channels.

The HIV drug market consists of sales of Tivicay, Triumeq, Truvada, and Vemlidy. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.